Citius Pharmaceuticals, Inc. - The Bradford Era

Press Releases

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc.

February 14, 2025

CRANFORD, N.J. , Feb. 14, 2025 /PRNewswire/ --Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical comp...

Press Releases

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Citius Pharmaceuticals, Inc.

January 8, 2025

CRANFORD, N.J. , Jan. 8, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical compa...

Press Releases

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

Citius Pharmaceuticals, Inc.

January 7, 2025

CRANFORD, N.J. , Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused ...

Press Releases

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc.

December 27, 2024

Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("...

Press Releases

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

Citius Pharmaceuticals, Inc.

November 25, 2024

CRANFORD, N.J. , Nov. 25, 2024 /PRNewswire/ --Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical comp...

Press Releases

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

Citius Pharmaceuticals, Inc.

November 22, 2024

CRANFORD, N.J. , Nov. 22, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) announced today that it ...

Press Releases

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering

Citius Pharmaceuticals, Inc.

November 18, 2024

CRANFORD, N.J. , Nov. 18, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical comp...

Press Releases

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering

Citius Pharmaceuticals, Inc.

November 15, 2024

CRANFORD, N.J. , Nov. 15, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical comp...

Press Releases

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors

Citius Pharmaceuticals, Inc.

November 11, 2024

Study, in patients with solid tumors focusing on gynecological malignant tumors such as ovarian, endometrial, and cervical, nearing completion with th...